爱普列特治疗良性前列腺增生临床疗效观察

The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia

目的:研究观察爱普列特治疗BPH的疗效和安全性。方法:60例患者分为两组,试验组30例,服用爱普列特每天两次,每次5mg,对照组30例,服用保列治每天一次,每次5mg,疗程6个月。结果:给药3个月后,爱普列特和保列治有效率分别为56.7%和60.0%,6个月后有效率分别为86.7%和90.0%,两组相比均差异无统计学意义(P>0.05)。不良反应发生率爱普列特组为10.0%(3/30),保列治组为13.3%(4/30),两者相比差异无统计学意义(P>0.05)。结论:爱普列特可明显改善BPH患者临床症状,不良反应发生率低,疗效和耐受性与保列治类似,是一种安全有效的治疗BPH的药物。

Objective：To study the efficacy and safety of epristeride in the treatment of benign prostatic hyperplasia （BPH） using an opened randomized controlled trial. Methods：60 BPH patients were enrolled in the trial, 30 of which were administered 5 mg epristeride twice daily for 180 days, and the rest were administered 5 mg proscar daily for 180 days as well. Results： After 3 months therapy, the effective rate of epristeride and proscar was 56.7% and 60.0% respectively, and 6 months later, the rate was 86.7% and 90.0% respectively. There was no statistical difference between the effective rate of epristeride and proscar （P〉0.05）, neither did in the adverse effect rate （epristeride10.0 % vs. proscar 13.3 %, P〉 0.05）. Conclusions： Epristeride could greatly relieve the clinic symptoms of BPH patients and adverse effects rarely occurred, which is an effective and safe drug for the treatment of BPH compared with proscar.